• Gilead Jun 22

    Gilead to Begin Human Trials for the Inhaled Version of Coronavirus Drug Remdesivir

    Gilead Sciences will begin human trials for an inhaled version of its antiviral drug remdesivir in August, the biotech company said Monday. Remdesivir, which was granted an emergency use authorization (EUA) from the Food and Drug Administration to treat patients hospitalized with Covid-19, is administered intravenously. The company told investors in April that it was looking to develop easier-to-administer versions of the drug,...

Contact Us